You've heard about the likes of Ozempic, Wegovy and Mounjaro, jabs which a growing number of people are taking in an attempt ...

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new challenger to blockbusters from Novo Nordisk A/S and Eli Lilly & Co.

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

With a first-in-class approval in China, Eli Lilly’s GLP-1 development engine has delivered yet again on the obesity front—although local biopharma outfit Innovent Biologics will be the one to ...

The U.S. trade deficit with Ireland has surged as $36 billion in hormone shipments for weight-loss and diabetes drugs were flown in to meet demand and avoid tariffs.

By Andrew Silver SHANGHAI (Reuters) -Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its ...

Novo Nordisk A/S and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their ...

Mazdutide is the first weight loss drug with dual GLP-1 and GCP (glucagon) receptor agonist, for which Innovent secured its China rights from Eli Lilly in 2019.

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap active ingredients from China ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of 10% to 15% of their body weight, roughly in line with results from a ...

New Delhi: Drug major Cipla is preparing to foray into the weight management segment in India, its MD and global CEO Umang ...